PLA2G7 and early-onset autosomal dominant Alzheimer disease: Lp-PLA2 inhibitor therapies have also been investigated in phase II trials for diabetic macular oedema (NCT01506895) and Alzheimer’s disease (NCT01428453), but these outcomes were not evaluated in the present study due to insufficient numbers of reported events.